<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775734</url>
  </required_header>
  <id_info>
    <org_study_id>AS1275</org_study_id>
    <nct_id>NCT02775734</nct_id>
  </id_info>
  <brief_title>NAC in CC Resistant PCOS After LOD</brief_title>
  <acronym>NAC</acronym>
  <official_title>N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized placebo-controlled double blind clinical trial will conducted in
      Ain Shams University maternity Hospital including 120 women diagnosed with clomiphene citrate
      resistant polycystic ovary syndrome. After laparoscopic ovarian drilling, they will be
      randomized to either receiving 50 mg oral clomiphene citrate twice daily and oral NAC 1,200
      mg/day for 5 days starting from cycle day 2 to cycle day 6 (group 1 = 60 patients) or
      clomiphene citrate only (group 2 = 60 patients). The primary outcome will be biochemical
      pregnancy rate, secondary outcomes include Clinical pregnancy rate, ovulation rate, live
      birth rate, number of follicles ≥ 18 mm and endometrial thickness at triggering ovulation,
      mid- luteal sub-endometrial blood flow indices, and incidence of side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follicles more than or equal 18 mm</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-ovulatory endometrial thickness</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid-luteal sub-endometrial doppler blood flow indices</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Clomiphene Citrate Resistant Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>N-acetyl-cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetyl-cysteine + Clomiphene citrate + LOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO N-acetyl-cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clomiphene citrate + LOD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl-cysteine</intervention_name>
    <description>N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling</description>
    <arm_group_label>N-acetyl-cysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene citrate</intervention_name>
    <description>Clomiphene citrate + Laparoscopic ovarian drilling</description>
    <arm_group_label>N-acetyl-cysteine</arm_group_label>
    <arm_group_label>NO N-acetyl-cysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 25 and 30 Kg/m 2.

          -  CC-resistant Polycystic ovary syndrome

        Exclusion Criteria:

          -  • Patients with BMI under 25 or over 30 Kg/m 2.

               -  Hyper or hypothyroidism, or hyperprolactinemia.

               -  Current or previous (within the last six months) use of oral contraceptives,
                  glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other
                  hormonal drugs.

               -  Intention to start a diet or a specific program of physical activity.

               -  Organic pelvic diseases.

               -  Tubal or male factor infertility.

               -  Interval of earlier treatment with any of the fertility drugs of less than 6
                  months.

               -  Contraindication to either:

                    -  Clomiphene citrate: liver disease, undiagnosed abnormal uterine bleeding,
                       uterine fibroids, endometrial cancer, ovarian enlargement or hyper
                       stimulation

                    -  HCG injection: ovarian enlargement or hyper stimulation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>N-acetyl-cysteine</keyword>
  <keyword>Clomiphene citrate</keyword>
  <keyword>Clomiphene citrate resistant</keyword>
  <keyword>Laparoscopic ovarian drilling</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

